Advertisement

Hepatozelluläres Karzinom

  • C. J. A. Punt

Zusammenfassung

90% primär maligner Lebertumoren sind hepatozelluläre Karzinome (HCC); in den übrigen Fällen handelt es sich meist um Cholangiokarzinome, Hepatoblastome (Kinder) und Sarkome. 60–80% der HCC sind mit einer Zirrhose assoziiert, in der westlichen Welt meist infolge eines Alkoholabusus. Die fibrolamelläre Variante des HCC ist meist nicht mit einer Zirrhose oder Hepatitis-B-Infektion assoziiert. Fernmetastasen finden sich am häufigsten in Lunge und Knochen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Cook CG, Moosa B (1985) Hepatocelular carcinoma: one of the world’s most common malignancies. Am J Med 233: 705–708Google Scholar
  2. 2.
    Lotze MT, Flickinger JC, Carr BI (1993) Hepatobiliary neoplasms. In: Cancer, Principles and Practice of Oncology. DeVita VT Jr, Hellmann S, Rosenberg SA (eds). 4th edition, JB Lippincott Co. Philadelphia, p 883–914Google Scholar
  3. 3.
    Lim RC, Bongard FS (1984) Hepatocellular carcinoma — changing concepts in diagnosis and management. Arch Surg 119: 637–642PubMedCrossRefGoogle Scholar
  4. 4.
    Yumoto Y, Umeda M, Oshima K et al. (1994) Estimation of remnant liver function before hepatectomy by means of technetium-99m-diethylenetriamine-pentaacetic acid galactosyl human albumin. Cancer Chemother Pharmacol 33: S1 - S6PubMedCrossRefGoogle Scholar
  5. 5.
    Ringe B, Pichlmayer R, Wittekind C, Tusch G (1991) Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients: World J Surg 15: 270–285PubMedGoogle Scholar
  6. 6.
    Nagorney DM, Van Heerden JA, Illstrup DM, Adson MA (1989) Primary hepatic malignancy: surgical management and determinants of survival. Surgery 106: 740–749PubMedGoogle Scholar
  7. 7.
    Okuda K, Ohstuki T, Obata H et al. (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 56: 918–928PubMedCrossRefGoogle Scholar
  8. 8.
    Yamanaka N, Okamoto E, Foyosaka A et al. (1990) Prognostic factors after hepatectomy for hepatocellular carcinoma. Cancer 65: 1104–1110PubMedCrossRefGoogle Scholar
  9. 9.
    Nagasue N, Yukaya H, Ogawa Y, Sasaki Y, Chang YC, Niimi K (1986) Second hepatic resection for recurrent hepatocellular carcinoma. Br J Surg 73: 434–438PubMedCrossRefGoogle Scholar
  10. 10.
    Iwatsuki S, Starzl TE, Sheahan DA et al. (1991) Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214: 221–229PubMedCrossRefGoogle Scholar
  11. 11.
    Langer B, Greig PD, Taylor BR (1994) Surgical resection and transplantation for hepatocellular carcinoma. In: Hepatobiliary Cancer. Sugarbaker PH (ed). Kluwer Academic Publishers Boston, p 231–240CrossRefGoogle Scholar
  12. 12.
    Nerenstone SR, Ihde DC, Friedman MA (1988) Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15: 1–31PubMedCrossRefGoogle Scholar
  13. 13.
    Venook AP (1994) Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12: 1323–1334PubMedGoogle Scholar
  14. 14.
    Patt YZ, Charnsangavej C, Yoffe B et al. (1994) Hepatic arterial infusion of floxuridine, leucovorin doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12: 1204–1211PubMedGoogle Scholar
  15. 15.
    Stone MJ, Klintmalm G, Polter D, Husberg B, Egorin MJ (1989) Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. Transplantation 48: 344–347PubMedCrossRefGoogle Scholar
  16. 16.
    Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl TE (1993) Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Transplant Proc 25: 1128–1129PubMedGoogle Scholar
  17. 17.
    Ohnishi K, Tsuchiya S, Nakayama T et al. (1984) Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. Radiology 152: 51–55PubMedGoogle Scholar
  18. 18.
    Kobayashi H, Hidaka H, Kajiya Y et al. (1986) Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn 27: 139–147Google Scholar
  19. 19.
    Ohnishi K, Sugita S, Nomura F, Iida S, Tanabe Y (1987) Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma. Am J Gastroenterol 82: 876–879PubMedGoogle Scholar
  20. 20.
    Sasaki Y, Imaoka S, Kasugai H et al. (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60: 1194–1203PubMedCrossRefGoogle Scholar
  21. 21.
    Lin DY, Liaw YF, Lee TY, Lai CM (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma — a randomized controlled trial. Gastroenterology 94: 453–456PubMedGoogle Scholar
  22. 22.
    Kasugai H, Kojima J, Tatsuta M et al. (1989) Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodidzed oil. Gastroenterology 97:965–971Google Scholar
  23. 23.
    Kanematsu T, Furuta T, Takenaka K et al. (1989) A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10: 98–102PubMedCrossRefGoogle Scholar
  24. 24.
    Shibata J, Fujiyama S, Sata T et al. (1989) Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 64: 1586–1594PubMedCrossRefGoogle Scholar
  25. 25.
    Venook AP, Stagg RJ, Lewis BJ et al. (1990) Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8: 1108–1114PubMedGoogle Scholar
  26. 26.
    Beppu T, Ohara C, Yamaguchi Y et al. (1991) A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer 68: 2555–2560PubMedCrossRefGoogle Scholar
  27. 27.
    Stuart K, Stokes K, Jenkins R, Trey C, Clouse M (1993) Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 72: 3202–3209PubMedCrossRefGoogle Scholar
  28. 28.
    Yamada T, Makita F, Takehara K et al. (1994) Evaluation of the therapeutic effect of TAE on primary liver cancer. Cancer Chemother Pharmacol 33: S55 – S59PubMedCrossRefGoogle Scholar
  29. 29.
    Nishimine K, Uchida H, Matsuo N et al. (1994) Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 33: S60 – S68PubMedCrossRefGoogle Scholar
  30. 30.
    Yodono H, Takekawa SD, Tarusawa K et al. (1994) Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE). Cancer Chemother Pharmacol 33: S70 – S83CrossRefGoogle Scholar
  31. 31.
    Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H (1994) Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 33: S84 – S88PubMedCrossRefGoogle Scholar
  32. 32.
    Nakamura H, Mitani T, Murakami T et al. (1994) Five-year surival after trans-catheter chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S89 – S92PubMedCrossRefGoogle Scholar
  33. 33.
    Kawai S, Tani M, Okamura J et al. (1994) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cancer Chemother Pharmacol 33: 597–5102Google Scholar
  34. 34.
    Bronowocki JP, Vetter D, Dumas F et al. (1994) Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 74: 16–24CrossRefGoogle Scholar
  35. 35.
    Shiina S, Tagawa K, Unuma T et al. (1990) Percutaneous ethanol injection therapy of hepatocellular carcinoma: analysis of 77 patients. AJR 155: 1221–1226PubMedCrossRefGoogle Scholar
  36. 36.
    Livraghi T, Bolondi L, Lazzarani S et al. (1992) Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 69: 925–929Google Scholar
  37. 37.
    Horiguchi Y, Sekoguchi B, Imai H et al. (1994) Treatment of choice for unresectable small liver cancer: percutaneous ethanol injection therapy or transarterial chemoembolization therapy. Cancer Chemother Pharmacol 33: 5111–5114CrossRefGoogle Scholar
  38. 38.
    Kato T, Saito Y, Niwa M, Ishiguro J, Ogoshi K (1994) Combination therapy of transcatheter chemoembolization and percutaneous ethanol injection therapy for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S115 — S118PubMedCrossRefGoogle Scholar
  39. 39.
    Tateishi H, Kinuta M, Furukawa J et al. (1994) Follow-up study of combination treatment (TAE and PEIT) for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S119 – S123PubMedCrossRefGoogle Scholar
  40. 40.
    Farinati F, Salvagnini M, De Maria N et al. (1990) Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 11: 297–301PubMedCrossRefGoogle Scholar
  41. 41.
    Engstrom PF, Levin B, Moertel CG, Schott A (1990) A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 65: 2641–2643PubMedCrossRefGoogle Scholar
  42. 42.
    Gupta S, Lorula J (1988) Failure of ketoconazole as anti-androgen therapy in nonresectable hepatocellular carcinoma. J Clin Gastroenterol 10: 651–654PubMedCrossRefGoogle Scholar
  43. 43.
    Lai CL, Wu PC, Lok ASF et al. (1989) Recombinant a2-interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 60: 928–933PubMedCrossRefGoogle Scholar
  44. 44.
    Lai CL, Lau JYN, Wu PC et al. (1993) Recombinant interferon-a in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17: 389–394PubMedCrossRefGoogle Scholar
  45. 45.
    Colleoni M, Buzzoni R, Bajetta E et al. (1993) A phase II study of motoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 72: 3196–3201PubMedCrossRefGoogle Scholar
  46. 46.
    Kardinal CG, Moertel CG, Wieand HA et al. (1993) Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 71: 2187–2190PubMedCrossRefGoogle Scholar
  47. 47.
    Order SE, Stillwagon GB, Klein JL et al. (1985) Iodine 131 antiferrin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol 3: 1573–1582PubMedGoogle Scholar
  48. 48.
    Sitzmann JU, Order SE, Klein JL, Leichner PK, Fishman EK, Smith GW (1987) Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 5: 1566–1573PubMedGoogle Scholar
  49. 49.
    Order S, Pajak T, Leibel S et al. (1991) A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 20: 953–963PubMedCrossRefGoogle Scholar
  50. 50.
    Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS (1993) Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong Biotherapy pilot study trial. Cancer 71: 3633–3639Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • C. J. A. Punt

There are no affiliations available

Personalised recommendations